公开(公告)号：US20180201890A1

公开(公告)日：2018-07-19

申请号：US15743913

申请日：2016-07-14

Applicant: DAIKIN INDUSTRIES, LTD. ,  OTSUKA PHARMACEUTICAL FACTORY, INC.

Inventor： Tatsuya HIGUCHI ,  Kozue KOMAZAWA ,  Yoshiko MOHARA ,  Takayuki DEMPO ,  Masuhiro NISHIMURA

IPC: C12M1/00 ,  C12N5/0775 ,  C09D127/18 ,  C09D127/20 ,  C09D129/10 ,  A61K35/28

CPC classification number: C12M23/20 ,  A61K35/28 ,  C09D127/18 ,  C09D127/20 ,  C09D129/10 ,  C12M23/14 ,  C12N5/0663

Abstract: When mammal cells are administered by using a container whose surface in contact with the mammal cells is formed of a fluororesin material at least partially having a —CF3 terminal group or a container whose surface in contact with the mammal cells is formed of a fluororesin material having a total number of non-fluorinated group terminals and —CF2H group terminals in the fluororesin of 70 or less per 1×106 carbon atoms, or mammal cells are stored or cultured in such a container, the cell adhesion on the container inner surface and the cell survival rate reduction can effectively be suppressed. Therefore, by using these containers, a mammal cell-containing liquid having a high concentration and a high proportion of living cells can be administered, stored or prepared, which contributes to regenerative medicine using the mammal cell-containing liquid (suspension liquid).